45 The Drug Rediscovery Protocol Extended Data Table 1. Available drugs and matching rules (continued) Supplier Drug Indications Available - Patients eligible for on-label nilotinib, or for the SUSTRENIM or NAUT trial Trametinib + MAP2K1/2/4, MAP3K1 or NRAS activating mutations November 2016 - Patients eligible for on-label trametinib or for the KRAS trial Pfizer Axitinib + FLT1/4 or KDR activating mutations, amplifications or overexpression October 2017 - Patients eligible for on-label axitinib Crizotinib + ALK, MET, MST1R, ROS1 activating mutations, amplifications, fusions or overexpression October 2017 - Patients eligible for on-label crizotinib, and tumors with known ALK-resistance mutations Sunitinib + CSF1R, FGFR1/2/3, FLT1/3/4, KDR, KIT, PDGFRα/β, RET, activating mutations, amplifications, fusions or overexpression October 2017 - Patients eligible for on-label sunitinib, and tumors with KIT D842V mutations Palbociclib + CCND1, CDK4(R24)/6, FLT3, PIK3R4, GSK3b activating mutations, amplifications or overexpression. CDKN2A inactivating mutations. August 2018 - Patients eligible for on-label palbociclib. Roche Erlotinib + EGFR activating mutations or exon 19 deletions in the region E746_E759 September 2016 - Patients eligible for on-label erlotinib, and tumors with known EGFR-resistance mutations Trastuzumab and pertuzumab + ERBB2 activating mutations, amplifications exon 20 insertions or overexpression September 2016 Patients eligible for on-label trastuzumab + pertuzumab or for the KAMELEON trial Vemurafenib and cobimetinib - BRAF V600D/E/K/R activating mutations September 2016 Patients eligible for on-label vemurafenib + cobimetinib, and tumors with MAP2K1/2 or NRAS mutations Vismodegib + PTCH1 activating mutations September 2016 - Patients eligible for on-label vismodegib, and tumors with known SMO-resistance mutations or with GLI2 amplification 2
RkJQdWJsaXNoZXIy MTk4NDMw